ALEC Trades Below Cash After $1.27B Genentech Deal

Alector stock analysis: $1.27B Genentech deal triggers negative EV — buy or sell?

👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_video&utm_medium=explainer_video&utm_campaign=freja_and_friends

In this deep dive, we break down Alector Inc (ALEC) and its pivotal transition following a landmark $1.27 billion global licensing agreement with Genentech for its Brain Carrier platform. With shares trading near $1.95 and a pro forma cash balance of $223.7 million creating a negative enterprise value, the key question for investors is whether its delivery technology can succeed in human clinical trials after legacy pipeline failures. Here’s everything you need to know before making a decision on ALEC.

🎯 SECTIONS:

- Executive Summary & Company Overview

- Strategic Pivot & Alector Brain Carrier (ABC) Platform

- Lead Programs: AL137 & $1.27B Genentech Deal

- Financial Health & Pro Forma Cash Runway

- Valuation Breakdown & Negative Enterprise Value

- Bull vs. Bear Case Scenario Analysis

- Key Risks & 2027 Clinical Catalysts

- Final Investment Verdict